Skip survey header

PROSCA 2020 case 4 - Bahl

Thank You!

Your case challenge

View case
 
What would Amit Bahl do?



This patient with mCRPC has progression of disease within 12 months of abiraterone. This aspect was addressed in the CARD study where patients were randomised to receive either cabazitaxel or the second androgen receptor-targeted therapy (ART). The results from this study show that across all subgroups cabazitaxel performed better than the second ART.

References:
  • de Wit R, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019 Dec 26;381(26):2506-18.
  • Fizazi K. Pain response and health-related quality of life analysis in patients with metastatic castration-resistant prostate cancer receiving cabazitaxel versus abiraterone or enzalutamide in the CARD study. J Clin Oncol 2020;38(Suppl 6):4(abs.16)
 

What would Amit Bahl do?

This patient with mCRPC has progression of disease within 12 months of abiraterone. This aspect was addressed in the CARD study where patients were randomised to receive either cabazitaxel or the second androgen receptor-targeted therapy (ART). The results from this study show that across all subgroups cabazitaxel performed better than the second ART.

References:
  • de Wit R, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019 Dec 26;381(26):2506-18.
  • Fizazi K. Pain response and health-related quality of life analysis in patients with metastatic castration-resistant prostate cancer receiving cabazitaxel versus abiraterone or enzalutamide in the CARD study. J Clin Oncol 2020;38(Suppl 6):4(abs.16)
I hope you can join us during the live panel discussion of virtual PROSCA 2020 on 14 October to further discuss these data.
Reserve your seat